Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Belantamab mafodotina y lenalidomida para el tratamiento del mieloma múltiple en pacientes con enfermedad residual mínima positiva después de un trasplante de células madre

14 de octubre de 2026 actualizado por: Roswell Park Cancer Institute

Ensayo de fase 2 del tratamiento de consolidación con belantamab mafodotin en pacientes con mieloma múltiple y positividad para EMR después de un trasplante autólogo de células madre

This phase II trial investigates the effect of belantamab mafodotin and lenalidomide on minimal residual disease negative rates in patients with multiple myeloma with minimal residual disease positive after stem cell transplant. Belantamab mafodotin is a monoclonal antibody, called belantamab, linked to a chemotherapy drug, called mafodotin. Belantamab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as B-cell maturation antigen (BCMA) receptors, and delivers mafodotin to kill them. Lenalidomide may help block the formation of growths that may become cancer, and is used as a standard of care treatment for multiple myeloma. Giving belantamab mafodotin and lenalidomide may help to maintain minimal residual disease negativity in patients with multiple myeloma.

Descripción general del estudio

Estado

Activo, no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

PRIMARY OBJECTIVE:

I. Assess the minimal residual disease (MRD) negative rate after 6 cycles of post autologous stem cell transplant consolidation with belantamab mafodotin and lenalidomide.

SECONDARY OBJECTIVE:

I. Assess sustained MRD negative rate, progression free survival (PFS) and overall survival (OS).

OUTLINE:

Patients receive belantamab mafodotin intravenously (IV) over 30 minutes on day 1 and lenalidomide orally (PO) once daily (QD) on days 1-28. Treatment repeats every 8 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 12 weeks and the periodically for up to 5 years.

Tipo de estudio

Intervencionista

Inscripción (Actual)

4

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • New York
      • Buffalo, New York, Estados Unidos, 14263
        • Roswell Park Cancer Institute

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Age >= 18 years of age at time of consent

  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

  • Histologically or cytologically confirmed diagnosis of multiple myeloma (MM) as defined according to International Myeloma Working Group (IMWG), 2016 criteria, and

    • Patient is considered transplant eligible, and
    • Is not MRD negative complete response (CR) after high dose chemotherapy
  • Absolute neutrophil count (ANC) >= 1.5 X 10^9/L (within 14 days of first dose of study treatment)

  • Hemoglobin >= 8.0 g/dL (within 14 days of first dose of study treatment)

  • Platelets >= 75 X 10^9/L (within 14 days of first dose of study treatment)

  • Total bilirubin =< 1.5 X upper limit of normal (ULN) (isolated bilirubin >= 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%) (within 14 days of first dose of study treatment)

  • Alanine aminotransferase (ALT) =< 2.5 X ULN or < 5 times ULN if documented liver infiltration (within 14 days of first dose of study treatment)

  • Estimated glomerular filtration rate (eGFR) >= 30 mL/min/ 1.73 m^2 (within 14 days of first dose of study treatment)

  • Spot urine (albumin/creatinine ratios (spot urine) < 500 mg/g (56 mg/mmol) OR urine dipstick Negative/trace (if >= 1+ only eligible if confirmed =< 500 mg/g (56 mg/mmol) by albumin/creatinine ratio (spot urine from first void) (within 14 days of first dose of study treatment)

  • A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

    • Not a woman of childbearing potential (WOCBP) OR
    • A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 4 months after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period
  • Female participants of childbearing potential are to have a negative serum pregnancy test within 24 hours before the first dose of study intervention

  • A male participant must agree to use an adequate method of contraception (as described below) during the treatment period and for at least 6 months after the last dose of study treatment to allow for clearance of any altered sperm, along with the following:

    • Refrain from donating sperm PLUS either:

      • Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent. OR
      • Must agree to use contraception/barrier
  • All prior treatment-related toxicities (defined by National Cancer Institute- Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 5.0) must be =< grade 1 at the time of enrolment except for alopecia

  • Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure

Exclusion Criteria:

  • Evidence of active bleeding requiring intervention within the last four weeks prior to first dose of study treatment

  • Current corneal epithelial disease except mild changes in corneal epithelium

  • Any major surgery within the last four weeks of first dose of study treatment

  • Use of contact lenses while participating in this study

  • Participant must not have had plasmapheresis within 7 days prior to first dose of study treatment

  • Presence of active renal condition (infection, requirement for dialysis or any other condition that could affect patient's safety). Patients with isolated proteinuria resulting from MM are eligible

  • Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere with patient's safety or compliance to the study procedures

  • Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. Note: Stable chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if patient otherwise meets entry criteria

  • Malignancies other than disease under study, unless the second malignancy has been medically stable for at least 2 years and, in the opinion of the principal investigators, will not affect the evaluation of the effects of clinical trial treatments on the currently targeted malignancy. Participants with curatively treated non-melanoma skin cancer may be enrolled without a 2-year restriction

  • Evidence of cardiovascular risk including any of the following:

    • Evidence of current clinically significant uncontrolled arrhythmias, including clinically significant electrocardiography (EKG) abnormalities such as 2nd degree (type II) or 3rd degree atrioventricular (AV) block.
    • History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within two months of first dose.
    • Class III or IV heart failure as defined by the New York Heart Association functional classification system.
    • Uncontrolled hypertension
  • Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to belantamab mafodotin or lenalidomide

  • Active infection requiring antibiotic, antiviral, or antifungal treatment

  • Known human immunodeficiency virus (HIV) infection

  • Presence of hepatitis B surface antigen (HBsAg), at or within 3 months of registration Note: If Hepatitis B core antibody (HBcAb) present, see additional monitoring recommendations

  • Positive hepatitis C antibody test result or positive hepatitis C ribonucleic acid (RNA) test result at or within 3 months prior registration. Note: Patients with positive hepatitis C antibody due to prior resolved disease can be eligible, only if a confirmatory negative hepatitis C RNA test is obtained.

    • Note: Hepatitis RNA testing is optional and patients with negative hepatitis C antibody test are not required to also undergo hepatitis C RNA testing
  • Best corrected visual acuity in the worst seeing eye worse than 20/100 (Snellen equivalent). Participants with vision worse than 20/100 due to a treatable condition (e.g., cataract) may be considered on an individual case basis within 6 months before registration

  • Use of an investigational drug within 14 days of first dose of study treatment or five half-lives, whichever is shorter, preceding the first dose of study drug. Prior treatment with a monoclonal antibody within 30 days of first dose of study treatment

  • Previously progressed on treatment with belantamab mafodotin

  • Pregnant or lactating female participants

  • Unwilling or unable to follow protocol requirements

  • Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Treatment (belantamab mafodotin, lenalidomide)

Patients receive belantamab mafodotin IV over 30 minutes on day 1 and lenalidomide PO QD on days 1-28. Treatment repeats every 8 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity.

Given PO

Otros nombres:
  • CC-5013
  • Revlimid
  • CC5013
  • CDC 501

Given IV

Otros nombres:
  • Belantamab Mafodotin-blmf
  • Blenrep
  • GSK2857916
  • J6M0-mcMMAF

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Minimal residual disease (MRD) negative rate
Periodo de tiempo: After 6 cycles of post-transplant consolidation with belantamab mafodotin and lenalidomide (1 cycle = 8 weeks)

A 90% confidence interval about true 6-month post-consolidation MRD negative rate will be obtained.

After 6 cycles of post-transplant consolidation with belantamab mafodotin and lenalidomide (1 cycle = 8 weeks)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Tasa negativa sostenida de MRD
Periodo de tiempo: 1 año después del final de la consolidación
1 año después del final de la consolidación
Progression-free survival
Periodo de tiempo: Time from the start of consolidation therapy until disease progression death, due to disease, or last disease evaluation, assessed up to 5 years

Will be summarized using standard Kaplan-Meier methods, with estimates of the median obtained with 90% confidence intervals.

Time from the start of consolidation therapy until disease progression death, due to disease, or last disease evaluation, assessed up to 5 years
Overall survival
Periodo de tiempo: Time from the start of consolidation until death due to any cause or last follow-up, assessed up to 5 years

Will be summarized using standard Kaplan-Meier methods, with estimates of the median obtained with 90% confidence intervals.

Time from the start of consolidation until death due to any cause or last follow-up, assessed up to 5 years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Jens Hillengass, Roswell Park Cancer Institute

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

19 de agosto de 2024

Finalización primaria (Actual)

29 de julio de 2026

Finalización del estudio (Estimado)

29 de julio de 2027

Fechas de registro del estudio

Enviado por primera vez

3 de mayo de 2021

Primero enviado que cumplió con los criterios de control de calidad

4 de mayo de 2021

Publicado por primera vez (Actual)

6 de mayo de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

14 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • I 797720
  • I 797720 (Otro identificador: Roswell Park Cancer Institute)
  • NCI-2021-02349 (Identificador de registro: CTRP (Clinical Trial Reporting Program))

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .